CES 2026 marks a vibe shift as generative AI leaves the screen for the physical world, led by NVIDIA, Qualcomm, and Boston ...
AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback